SPONSOR
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Total Trials
6
Recruiting
6
Phases
Phase 3, Phase 1, Phase 2
Conditions studied: Type 2 DiabetesObesity & OverweightAdvanced Solid TumorsRefractory LymphomaRelapsed Hematologic MalignancyObesityOverweight SubjectHealthy SubjectsHepatic ImpairmentHealthy Volunteers
NCT07193459 Phase 3
Recruiting
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes
NCT07279194 Phase 3
Recruiting
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Obesity & Overweight
NCT06615193 Phase 1
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Advanced Solid Tumors
NCT06886126 Phase 2
Recruiting
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
Obesity
NCT07331389 Phase 1
Recruiting
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
Overweight Subject
NCT06985615 Phase 1
Recruiting
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
Hepatic Impairment